QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode-Reference-Cited by-同舟云学术

QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode

Published:2015-07-02 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Chen Yuan-Yuan,Li Quan,Pan Chun-Shui,Yan Li,Fan Jing-Yu,He Ke,Sun Kai,Liu Yu-Ying,Chen Qing-Fang,Bai Yan,Wang Chuan-She,He Bing,Lv Ai-Ping,Han Jing-Yan

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep11802.pdf

Reference45 articles.

1. Hua, Y., Zhang, Y. & Ren, J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J. Cell. Mol. Med. 16, 83–95, 10.1111/j.1582-4934.2011.01307.x (2012).

2. Frohlich, E. D. & Susic, D. Pressure overload. Heart Fail Clin 8, 21–32, 10.1016/j.hfc.2011.08.005 (2012).

3. Rosca, M. G., Tandler, B. & Hoppel, C. L. Mitochondria in cardiac hypertrophy and heart failure. J. Mol. Cell. Cardiol. 55, 31–41, 10.1016/j.yjmcc.2012.09.002 (2013).

4. Komuro, I. Molecular mechanism of cardiac hypertrophy and development. Jpn. Circ. J. 65, 353–358 (2001).

5. Sag, C. M., Santos, C. X. & Shah, A. M. Redox regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 73, 103–111, 10.1016/j.yjmcc.2014.02.002 (2014).

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCMM: A unified database for traditional Chinese medicine modernization and therapeutic innovations;Computational and Structural Biotechnology Journal;2024-12

2. Clinical evidence and potential mechanisms of traditional Chinese medicine for refractory heart failure: a literature review and perspectives;Frontiers in Cardiovascular Medicine;2024-04-23

3. QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver;Phytomedicine;2024-01

4. QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway;Journal of Ethnopharmacology;2023-10

5. Shexiang Baoxin Pill treats acute myocardial infarction by promoting angiogenesis via GDF15-TRPV4 signaling;Biomedicine & Pharmacotherapy;2023-09